Hikma Pharmaceuticals’ (HIK) “Buy” Rating Reiterated at Citigroup

Hikma Pharmaceuticals (LON:HIK)‘s stock had its “buy” rating reaffirmed by equities researchers at Citigroup in a research report issued to clients and investors on Thursday,Digital Look reports.

A number of other analysts have also commented on HIK. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating and set a GBX 195 price target on shares of Hikma Pharmaceuticals in a report on Monday, June 22nd. Jefferies Financial Group lifted their target price on Hikma Pharmaceuticals from GBX 1,850 to GBX 1,870 and gave the stock a “buy” rating in a research note on Tuesday, May 5th. Finally, Berenberg Bank reissued a “buy” rating and issued a GBX 1,800 price target on shares of Hikma Pharmaceuticals in a report on Tuesday, April 28th. Six equities research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, Hikma Pharmaceuticals presently has a consensus rating of “Buy” and a consensus target price of GBX 1,687.

Hikma Pharmaceuticals Stock Performance

Shares of HIK stock opened at GBX 1,516 on Thursday. Hikma Pharmaceuticals has a one year low of GBX 1,187 and a one year high of GBX 2,052. The company has a market cap of £3.19 billion, a P/E ratio of 8.38, a P/E/G ratio of 2.38 and a beta of 0.65. The firm has a 50-day moving average of GBX 1,487.53 and a 200-day moving average of GBX 1,448.63. The company has a debt-to-equity ratio of 61.84, a current ratio of 1.82 and a quick ratio of 1.27.

About Hikma Pharmaceuticals

At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly. We are a trusted, reliable partner and dependable source of over 820+ (as of Feb 2026) high-quality generic, specialty and branded pharmaceutical products that hospitals, physicians and pharmacists need to treat their patients across North America, MENA and Europe.